ImmunoMax

At Verified Peptides, we want to lead with the single most important classification fact about ImmunoMax: it is not a peptide. Despite carrying a peptide-suggestive commercial name and appearing on Khavinson-adjacent "research peptide" name lists, ImmunoMax is a water-soluble acidic peptidoglycan (WSAP), a naturally occurring, heterogeneous high-molecular-weight biopolymer extracted from the sprouts of the potato plant (Solanum tuberosum). It is manufactured by the Russian pharmaceutical company Avexima JSC and registered as a drug by Russia's Ministry of Health for antiviral and immunomodulating use, including in the treatment of infections caused by human papillomavirus (HPV), mycoplasma, chlamydia, and ureaplasma.

Structurally, ImmunoMax is a complex of polysaccharide, peptide, and lipid components rather than a discrete, single molecule — reported molecular weight figures span an unusually wide range, roughly 500 to 17,000 kilodaltons, reflecting genuine polydispersity (a mixture of many differently-sized molecular fragments) rather than measurement imprecision around one true value. This places ImmunoMax in a meaningfully different category from every other compound in this Phase 4 build batch: even Glandokort, also a natural multi-component complex rather than a single peptide, is at least described as a peptide-dominant tissue extract, whereas ImmunoMax is explicitly classified in its own regulatory and manufacturing documentation as a peptidoglycan — a polysaccharide-based biopolymer class that includes peptide components but is not itself peptide chemistry in the sense used for the rest of this catalog.

Production reportedly involves aqueous extraction from potato sprouts, ultrafiltration, an acidic precipitation step, alkali treatment, dialysis, and gel permeation chromatography purification — a process more characteristic of natural biopolymer/glycoconjugate isolation than of the solid-phase peptide synthesis used to manufacture the single-sequence synthetic peptides elsewhere in this catalog.

At Verified Peptides, we want to be direct about ImmunoMax's evidence base, which is unusual in a specific way: unlike most other compounds in this catalog, ImmunoMax IS an actual registered pharmaceutical drug in Russia, used clinically there for antiviral and immunomodulating indications — but we could not locate any PubMed-indexed primary research publication specifically evaluating it, despite a direct, targeted PubMed search. The clearest specific clinical reference we located is a conference-style publication, "Immunomax® therapy to obtain relief in papilloma virus infections, prostatitis, and prostate carcinoma," appearing in European Urology Supplements — a real, named, findable reference, but one we could not access in full text, and one that does not appear to be indexed in PubMed as a standard peer-reviewed original research article. We are disclosing this reference by title rather than omitting it, but explicitly flagging that we could not independently verify its study design, sample size, or results.

This puts ImmunoMax in an unusual position relative to the rest of this catalog: it is simultaneously the compound in this batch with the clearest real-world regulatory and clinical-use footprint (an actual government-registered drug with defined approved indications in Russia) and one with essentially no independently verifiable, PubMed-indexed primary research supporting those specific indications that we could locate. Researchers should not read "registered drug in Russia" as equivalent to "supported by a body of independently verifiable peer-reviewed clinical trial data" the way that phrase might imply for an FDA-approved compound — Russian drug registration and Western peer-reviewed publication are separate processes with different evidentiary requirements, and the gap between them here is significant.

No FDA, EMA, or other Western regulatory body has evaluated or approved ImmunoMax for any indication. At Verified Peptides, we sell research-grade ImmunoMax strictly for laboratory research, and we encourage researchers who want to rely on its reported antiviral/immunomodulating indications to seek out primary Russian-language regulatory and research documentation directly, since we were unable to independently verify the specific clinical claims through standard Western literature search.

It is worth situating ImmunoMax within a broader, independently well-established scientific field: plant- and microbe-derived biopolymers that activate innate immunity through pattern-recognition receptor pathways are a genuine, active area of immunology research, encompassing well-studied examples such as bacterial lipopolysaccharide, fungal beta-glucans, and various plant-derived polysaccharide immunostimulants used in both conventional and complementary medicine contexts internationally. This general field provides plausible scientific context for why a potato-derived peptidoglycan complex could have real immunostimulatory activity — but general plausibility for a broad compound class is not the same as compound-specific, independently verified evidence for ImmunoMax itself, and we do not want to blur that distinction for researchers evaluating this specific product.

ImmunoMax's placement on a "research peptides" build list alongside genuine amino-acid-sequence peptides is itself a useful illustration of how commercial and informal naming in this space does not reliably track underlying chemistry. Its peptidoglycan classification connects it, at a general immunological level, to a well-established area of mainstream immunology: bacterial cell-wall peptidoglycan fragments, particularly muramyl dipeptide, are independently and extensively documented to activate pattern-recognition receptor pathways (notably NOD2) and drive innate immune cytokine responses. ImmunoMax's plant-derived peptidoglycan is a different, less-studied member of a conceptually related biopolymer class, not the same well-characterized bacterial molecule.

The reported molecular weight range for ImmunoMax's active complex — roughly 500 to 17,000 kilodaltons — spans more than an order of magnitude, which is a genuinely unusual degree of polydispersity even for a natural biopolymer preparation. This breadth suggests the commercial product is likely a mixture of molecular fragments of quite different sizes rather than a tightly purified single macromolecular species, a meaningfully different situation from even Glandokort's natural adrenal-tissue peptide complex, which at least is described predominantly in peptide terms.

ImmunoMax's approved use profile in Russia — spanning human papillomavirus, mycoplasma, chlamydia, and ureaplasma infections — reflects a broad-spectrum antiviral/antimicrobial immunostimulant positioning rather than a single, narrowly targeted indication, consistent with a mechanism of general innate immune activation rather than pathogen-specific targeting.

Researchers should be aware that potato-derived compounds broadly include glycoalkaloids (a separate, well-studied class of Solanaceae plant compounds with known toxicity considerations at high exposure), which are chemically and functionally distinct from the acidic peptidoglycan complex that constitutes ImmunoMax — the two should not be conflated simply because both originate from the same plant.

The choice of potato sprouts specifically as a source material is itself notable: sprouting tissue in many plants, including potatoes, is a period of rapid growth and heightened biochemical defense activity, and it is this actively defending sprout tissue — rather than the tuber itself, which is the part of the potato plant normally consumed as food — that is reported to be the extraction source for ImmunoMax's active peptidoglycan complex.

At Verified Peptides, we require documentation of extraction and purification standards for research-grade ImmunoMax, since it is a natural plant-derived biopolymer complex rather than a synthesized single compound. Because ImmunoMax is inherently polydisperse — spanning a very broad molecular weight range rather than existing as one defined molecule — standard single-compound purity metrics such as HPLC purity percentage against one target molecular weight do not directly apply the way they do for a synthesized peptide.

We source exclusively from manufacturers operating under quality-controlled extraction and purification systems, and we recommend researchers request whatever batch documentation is available and treat any specific compositional consistency claims with appropriate caution given the inherent difficulty of fully characterizing a heterogeneous natural biopolymer complex compared to a single defined-sequence compound.

Given ImmunoMax's status as an actual registered pharmaceutical product in its country of origin, researchers should be particularly careful to distinguish clinical-grade material manufactured under Russian pharmaceutical regulatory standards from research-grade material sold for laboratory use, since these represent different quality and regulatory pathways even when derived from the same underlying biopolymer.

ImmunoMax is typically supplied as a lyophilized (freeze-dried) preparation for reconstitution, and should be stored in a cool, dry environment protected from light and moisture, consistent with standard storage guidance for lyophilized natural biopolymer preparations. At Verified Peptides, we ship material with packaging appropriate to preserve stability in transit.

Because ImmunoMax is a heterogeneous, high-molecular-weight natural complex rather than a single molecular species, its overall stability profile reflects the combined behavior of its constituent polysaccharide, peptide, and lipid fragments rather than one well-characterized degradation pathway. Researchers should follow the specific storage guidance provided with each lot's documentation and avoid exposure to excessive heat, humidity, or direct light.

Given the more limited independent analytical characterization available for a natural biopolymer complex of this kind compared to a single-sequence synthetic peptide, researchers relying on long-term storage stability data for ImmunoMax specifically should treat general biopolymer-storage principles as a reasonable but not compound-specifically validated guide.